Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Blood (2025) 146 (Supplement 1): 5501.

https://doi.org/10.1182/blood-2025-5501

Published: 2025

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Melody Tan, Josephine Giles, Patrizia Porazzi, Leonel Torres, Luca Paruzzo, Alberto Carturan, Wumesh KC, Yunlin Zhang, Raymone Pajarillo, E. John Wherry, Marco Ruella

Blood (2025) 146 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2025-4097

Published: 2025

Journal Articles

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Blood (2025) 146 (Supplement 1): 808.

https://doi.org/10.1182/blood-2025-808

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Journal Articles

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Heta Patel, Luca Paruzzo, Oxana Megherea, Matthew Ho, Thomas Luo, Dan Vogl, Shivani Kapur, Adam Waxman, Federico Stella, Alberto Carturan, Martina Pucillo, Antonio Imparato, Edward Stadtmauer, Alfred Garfall, Adam Cohen, Marco Ruella, Sandra Susanibar-Adaniya

Blood (2025) 146 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2025-3995

Published: 2025

Journal Articles

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, Bhoomi Madhu, Luca Paruzzo, Kecheng Han, Alexander Shestov, Chaoting Zhou, Jason Lin, Alberto Carturan, Patrizia Porazzi, Elise Chong, Stephen Schuster, Michael Milone, Christoph Thaiss, Maayan Levy, Marco Ruella

Blood (2025) 146 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2025-5903

Published: 2025

Journal Articles

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan, Mathew G. Angelos, Raymone Pajarillo, Jesse Rodriguez, Jaryse Harris, Yunlin Zhang, Ekta Singh, Andrew Lee, Ositadimma Ugwuanyi, Ruchi P. Patel, Puneeth Guruprasad, Jean Lemoine, Jong Hyun Cho, Patrizia Porazzi, Stephen J. Schuster, Marco Ruella

Blood (2024) 144 (Supplement 1): 504.

https://doi.org/10.1182/blood-2024-206061

Published: 2024

Journal Articles

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Siena Nason, Ziqi Yang, Guido Ghilardi, Luca Paruzzo, Alberto Carturan, Eugenio Fardella, Puneeth Guruprasad, Anushka Anant Padmanabhan, Tatiana Blanchard, Gerald Linette, Beatriz M. Carreno, Sandra Susanibar-Adaniya, Alfred L. Garfall, Marco Ruella, Patrizia Porazzi

Blood (2024) 144 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2024-206011

Published: 2024

Journal Articles

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood (2024) 144 (Supplement 1): 4.

https://doi.org/10.1182/blood-2024-208913

Published: 2024

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella

Blood (2024) 144 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2024-206544

Published: 2024

Journal Articles

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Blood (2023) 142 (Supplement 1): 768.

https://doi.org/10.1182/blood-2023-189633

Published: 2023

Journal Articles

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Patrizia Porazzi, Yusuke Isshiki, Guido Ghilardi, Siena Nason, Ziqi Yang, Alberto Carturan, Linhui Chen, Yunlin Zhang, Ruchi P. Patel, Puneeth Guruprasad, Ositadimma Ugwuanyi, Ivan J Cohen, Stephen J Schuster, Ari M Melnick, Wendy BÃ©guelin, Marco Ruella

Blood (2023) 142 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2023-182440

Published: 2023

Journal Articles

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2023-189369

Published: 2023

Journal Articles

Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes

Antonella Poloni, Alberto Carturan, Michelangelo Pianelli, Erika Morsia, Dorela Lame, Attilio Olivieri

Blood (2021) 138 (Supplement 1): 4667.

https://doi.org/10.1182/blood-2021-150303

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only